Background Although the international guideline recommends intravenous immunoglobulin (IVIG) as the first-line treatment for childhood idiopathic thrombocytopenia purpura (ITP) with life-threatening bleeding, ITP patients may not be able to access IVIG because of the limitation in health benefit packages especially in developing countries. There remains an important policy question as to whether IVIG used as a first-line treatment is worth the money spent. Thus, the objective of this study was to perform a cost-effectiveness analysis of adding IVIG to the standard treatment of platelet transfusion and corticosteroids, for the treatment of childhood ITP with life-threatening bleeding in the context of Thailand. Methods A cost-effectiveness analysis using a hybrid model consisting of a decision tree and Markov models was conducted with a societal perspective. The effectiveness and utility parameters were determined by systematic reviews, while costs and mortality parameters were determined using a retrospective electronic hospital database analysis. All costs were presented in 2012 US$. The discount rate of 3 % was applied for both costs and outcomes. One-way and probabilistic sensitivity analyses were also performed. Results The incremental cost-effectiveness ratio (ICER) was $3,172 per quality-adjusted life-year gained ($/ QALY) for the addition of IVIG versus standard treatment alone. The probability of response to corticosteroids was the most influential parameter on ICER. According to the willingness-to-pay of Thailand, of approximately $3,861/QALY, the probability of IVIG being cost effective was 33 %. Conclusions The addition of IVIG to standard treatment in the treatment of childhood ITP with life-threatening bleeding is possibly a cost-effective intervention in Thailand. However, our findings were highly sensitive. Policy makers may consider our findings as part of the information for their decision making Electronic supplementary material The online version of this article
Key Points for Decision Makers
Adding intravenous immunoglobulin to standard treatment in the treatment of childhood idiopathic thrombocytopenia purpura with life-threatening bleeding is possibly a cost-effective intervention in Thailand.
Policy makers may consider our findings as part of the information for their decision to include intravenous immunoglobulin in a health-benefit package process.
Relevant information including budget impact analysis, public health impact, and ethical issues should be considered as part of the final decision making.
Background
Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by the development of autoantibodies against platelets [1] . In children, ITP usually resolves itself without treatment with a favorable prognosis in 70-90 % of cases within 6 months [2] . Approximately 3 % of childhood ITP develops into more serious bleeding complications including severe epistaxis, mucosal hemorrhage, gastrointestinal bleeding, and intracranial hemorrhage (ICH) [3] [4] [5] [6] [7] . Hospitalization and emergency treatment are needed for those ITP patients with lifethreatening bleeding [8] . In this situation, the treatment is aimed at elevating the platelet count, as the increased risk of ICH is associated with a platelet count of \10,000-20,000/lL [9] . Several therapeutic options are available for the management of ITP patients with lifethreatening bleeding. The American Society of Hematology (ASH) and the British Society for Hematology (BSH) recommended intravenous immunoglobulin (IVIG) as part of a multimodality approach (i.e., in conjugation with platelet transfusion and corticosteroids) for the treatment of childhood ITP with life-threatening bleeding [10] [11] [12] .
Although a number of international clinical guidelines recommend IVIG as the first choice of treatment in ITP patients with life-threatening bleeding [10, 13, 14] , it is not included in basic health-benefit packages especially in developing countries such as Chile, Columbia, Argentina, Uruguay, and Thailand [15, 16] . Thus, ITP patients are unable to access IVIG or have to pay extra charges for IVIG to account for this additional healthcare need.
In Thailand, the use of IVIG for ITP patients with lifethreatening bleeding has been listed in the National List of Essential Medicine (NLEM) since 2008. However, the recommendation is to use IVIG after the failure of standard treatment (corticosteroids and/or platelet transfusion). This was not consistent with international guidelines because ASH and BSH recommended that childhood ITP patients with severe life-threatening bleeding should receive an appropriate regimen including IVIG, corticosteroids, and platelet transfusion to rapidly increase the platelet count [10, 12, 13] . Accordingly, IVIG should be used as a firstline treatment instead of a second-line treatment or after standard treatment failure.
The Health Technology Assessment (HTA) has been used around the world including the Asia Pacific region. Thailand has a long history of using the HTA for health policy decision making [17, 18] . Even though IVIG may be justified clinically for its use in childhood ITP patients with severe life-threatening bleeding, the question of whether IVIG is worth the money spent remains. This study aimed to perform a cost-effectiveness analysis of adding IVIG to standard treatment, platelet transfusion, and corticosteroids, for the treatment of childhood ITP patients with lifethreatening bleeding. This information can be used as supporting evidence for the Thai NLEM decision making.
Methods

Overall Description of Cost-Effectiveness Analysis
A hybrid model consisting of a decision tree and three Markov models was used to estimate relevant costs and health outcomes in ITP pediatric patients with life-threatening bleeding. The intervention of interest is the addition of IVIG to standard treatment compared with only standard treatment, which includes intravenous corticosteroids and platelet infusion. Our model was developed to mimic the natural history of ITP and clinical practice. The model was validated and revised through consultations with a health economist and clinicians. Because ITP can be a life-long condition, the lifetime horizon was chosen in this study. We undertook this study using a societal perspective as recommended by the Thailand's HTA guideline [19] .
We performed a cost-effectiveness analysis expressing findings as incremental cost/quality-adjusted life-years (QALYs) gained. Ethical approval was granted by the Committee on Human Rights Related to Research Involving Human Subjects, Naresuan University [Approval number: 55 02 04 0006].
Economic Model
The hybrid model consisting of a decision tree and Markov models is shown in Figs. 1 and 2 . A decision tree model was constructed to capture costs and outcomes of patients during hospitalization for their acute treatment. However, the entire effect of the treatment such as death and the long-term effect cannot be captured with only a decision tree model. Thus, it is important to estimate long-term clinical and economic outcomes associated with those patients who have survived using another model. Therefore, the Markov models with a 1-year cycle length were built to capture long-term benefits of IVIG after patients were discharged from a hospital. A hypothetical cohort of 1,000 childhood ITP with life-threatening bleeding weighing 20 kg and a platelet count \20,000/lL was simulated in the model. The definition of life-threatening bleeding is a condition with major bleedings including intracranial bleeding, gastrointestinal bleeding, and pulmonary bleeding and that required emergency treatment [20] .
During the hospitalization phase, there were two groups of outcomes after the initial treatment: 1) the non-response group; platelet counts did not increase to [20,000/lL after initial therapy and 2) the response group; platelet counts reached 20,000/lL [21] . The ''non-response group'' either underwent an emergency splenectomy or received supportive treatment. Thus, non-response patients were then divided into two subgroups, including splenectomized and non-splenectomized patients. The splenectomized patients could be further categorized into response and nonresponse groups according to whether the platelet count reached 150,000/lL after undergoing a splenectomy [10] . Patients could be discharged from a hospital as alive or dead. Among the alive ITP patients, they could be diagnosed as either acute or chronic ITP.
For the post-hospitalization phase, a total of three Markov models were constructed to represent three groups of patients including 1) patients with acute ITP, 2) patients with chronic ITP undergoing a splenectomy, and 3) patients with chronic ITP with no splenectomy (Fig. 2) . In the first Markov model, acute ITP patients required no treatment and usually improved spontaneously. Thus, they could live as the general population. In the second Markov model, chronic ITP patients undergoing splenectomy were either in complete remission or a no response health state. In the third Markov model, chronic ITP patients with no splenectomy may end up receiving splenectomy treatment, resulting in four health states including no splenectomy, splenectomy with complete remission, splenectomy with no response, and dead.
Input Parameters
Input parameters were obtained from a retrospective hospital database, literature search (local and international publications) and expert opinion. Five types of stakeholders, including health economists, healthcare providers (hematologists), patients, payers, and representatives from the pharmaceutical industry, participated in two stakeholder meetings, which were conducted with different objectives. The first meeting was to define the scope of the study including population, intervention, outcome, comparator and approval of our economic model, while the second meeting was to reach agreement on values and sources of all parameters in the model. See Supplementary Appendix 1 for more detail on stakeholder participants and stakeholder meetings.
Clinical Effectiveness and Probability Data: Hospitalization Phase
The overall risk ratio of response for IVIG was obtained from a meta-analysis of randomized controlled trials evaluating the effectiveness of IVIG compared with corticosteroids [22] . The overall risk ratio was 1. 
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A total of 593 patients with childhood ITP were identified from our hospital databases during the study period. Only 24 patients with childhood ITP with lifethreatening bleeding met inclusion criteria and were included in our study. Among patients with childhood ITP with a bleeding condition and a platelet level \20,000/lL, the response rate to corticosteroids was 60 % (95 % CI 15.7, 94.7 %). Among those ITP patients unresponsive to either IVIG or corticosteroids, some patients underwent a splenectomy. Given the absence of probability of undergoing a splenectomy after treatment failure in the literature, we requested two Thai hematologists to provide an estimate and a range of the probability of having a splenectomy (platelet count C150,000/lL) and no further treatment before discharge from a hospital, hash symbol no response is defined as a failure to achieve a platelet count [150,000/lL at any time after a splenectomy performed, as shown in Table 1 . To derive the probability of response to a splenectomy, we systematically reviewed published literature in PubMed from inception until June, 2013 and performed the meta-analysis (Supplementary Appendix 2). Based on a random-effects model under the DerSimonian and Laird method [23] , we found a total of six studies with the pooled response rate of 66.0 % (95 % CI 50.6, 81.6) and 63.0 % (95 % CI 44.4, 81.6) after no response to IVIG and corticosteroids, respectively [24] [25] [26] [27] [28] [29] . Case fatality rates among those responding and not responding to therapy were obtained from Thai hospital databases. The case fatality rates were 25 % (95 % CI 3.2, 61.5) and 33 % (95 % CI 0.8, 90.6) for those responsive and non-responsive patients.
A proportion of alive patients were diagnosed as chronic ITP. This estimate was obtained from our systematic review. (Supplementary Appendix 3) Based on six included studies, the probability of being diagnosed as chronic ITP was 21 % (95 % CI 14.1, 27.1) [30] [31] [32] [33] [34] [35] .
Clinical Effectiveness and Probability Data: PostHospitalization Phase
As ITP patients who were diagnosed as acute ITP do not require additional treatment and their platelet counts usually rise spontaneously, they can live as the general population. Thus, we applied the probability to death for this group in terms of the Thai population by using the agespecific Thai mortality rate [36] . Among those ITP patients who were diagnosed as chronic ITP, the choice of a splenectomy can be used when their platelet count decreased rapidly after discharge. To reflect the Thai context and because of the lack of evidence of life-long probability of a splenectomy in the literature, two Thai hematologists were requested to estimate the probability and its range, as shown in Table 1 .
Two possible outcomes of a splenectomy may ensue after the procedure, complete remission or no response. The probability of complete remission was retrieved from our systematic literature review and meta-analysis using a random-effects model under DerSimonian and Laird method [23] (Supplementary Appendix 1) . Based on a total of four included studies, the probability of complete remission was 76.0 % (95 % CI 69.5, 81.6) [30, [37] [38] [39] .
Because no additional treatment was required after undergoing a splenectomy among splenectomized patients with complete remission, the Thai population age-specific mortality rate was applied for their mortality rate [36] .
For non-response splenectomized patients, we estimated the risk of death based on the multiplication of Thai agespecific mortality [35] and relative risk (RR) of 1.4 (95 % CI 0.80, 2.3). This RR value was obtained from a cohort study that investigated the risk of death associated with a splenectomy adjusted for age, sex, and co-morbid conditions compared with the general population [40] .
Last, the mortality rate of patients with no splenectomy was obtained from the multiplication of RR of death for non-splenectomized patients compared with the general population [RR 3.5, 95 % CI 1. 43, 8.53 ] and the Thai agespecific mortality rate [36] . The latter RR was obtained from an indirect comparison analysis based on the findings of Yong et al. [40] .
Three main assumptions were used in our analysis. First, we assumed that all patients were admitted to the hospital and were discharged once the platelet count reached 20,000/lL. Second, patients responded to their initial therapy and did not require re-treatment during their hospitalization. Last, patients were not re-hospitalized with acute ITP for the length of their lifetime after their first hospitalization with ITP with life-threatening bleeding.
Cost Data
In our model, we calculated health resource use and healthcare costs from different sources including the hospital database, expert opinion, and the local standard costs [41] . From a societal perspective, we included both direct medical costs and direct non-medical costs. To make our manuscript easy to follow, we also separated costs into two parts: hospitalization and post-hospitalization. Each part reported the estimation of direct medical costs and direct non-medical costs, respectively. All costs were converted and reported in 2012 US$ [$1 = 31.08 Thai Baht (THB) [42] ] using the consumer price index [43] . A description of cost estimation has been illustrated in Supplementary Appendix 4.
Cost Data: Hospitalization Phase
For costs during hospitalization, all costs were calculated to represent cost per hospitalization. Our analysis included the direct medical costs related to the platelet enhancer (i.e., IVIG and splenectomy) and the treatment of thrombocytopenia. The first-line platelet enhancer was IVIG. We adopted cost of interventions (IVIG and splenectomy procedure) from standard local sources including the Drugs Medical Supplies Information Center (DMSIC) [44] and the standard cost list of the HTA [41] . We obtained the cost of IVIG drugs from the DMSIC (IVIG 5 % w/v [5 g/100 mL/vial] = $136 per vial) [44] . Based on the recommendation of the NLEM guideline and confirmation by expert opinion, we calculated the IVIG dose using 2 mg/kg/hospitalization for patients aged 9 years and weighing 20 kg, which would be a typical weight for this age. After failure from IVIG, patients may undertake splenectomy as their second choice of treatment. The cost of splenectomy was obtained from a standard cost list of the 
Cost Data: Post-Hospitalization Phase
For costs during the post-hospitalization phase, annual costs were applied for both direct and direct non-medical costs for each stage. First, for acute ITP, because acute ITP patients usually improve spontaneously and do not require further treatment after they are discharged from a hospital, we assumed that there was no cost during the post-hospitalization phase among these patients. Second, direct medical costs and direct non-medical costs for splenectomized patients with complete remission were estimated using a micro-costing approach [45] . Based on expert opinion, splenectomized patients with complete remission were estimated to require 10 physician visits and 10 complete blood count (CBC) tests during the first year after being discharged. The cost of a CBC and the cost of a physician visit were obtained from a standard cost list of HTA by Riewpaiboon et al. [41] . (cost of CBC$4/time and cost of physician visit $9/time in 2012 US$). Direct nonmedical costs for these patients were adopted from a standard cost list of HTA by Riewpaiboon et al. [41] and multiplied by total visits per year for each patient. Third, annual direct medical costs of non-response splenectomized patients and ITP patients with no splenectomy were calculated based on the actual patient's healthcare use. Medical care charges were converted to costs using a costto-charge ratios of 1.37 and 0.8, which were derived from a hospital in Bangkok and the northern part of Thailand, respectively [46] . Direct non-medical costs for these patients in the post-hospitalization phase were calculated using the same method as others and those costs were multiplied with the average number of visits per year for each patient. All cost parameters are shown in Table 1 .
Utility Data
As acute ITP patients can live as a healthy population, we applied 0.77 as the utility of the Thai general population for this group of patients [47] . For chronic patients both splenectomized and non-splenectomized, we applied their utility based on a systematic review. We performed a systemic review in PubMed up until June, 2013. Only studies that reported the utility of ITP patients who underwent a splenectomy and who did not or reported quality of life that can be converted to a utility were included in our analysis. The details of the review are shown in Supplementary Appendix 5. Only the study by Snyder et al. [48] met our criteria. The authors measured the health-related quality of life of 1,002 ITP patients using EuroQoL (EQ-5D) from the Platelet Disorder Support Association. The ITP patients had a mean age of 46 years and 76 % were female. In addition, the mean age at diagnosis of ITP was 37 years, with a mean duration of disease of 9 years, and 37 % had undergone a splenectomy. Splenectomized ITP patients' average EQ-5D index score was 0.77 versus 0.76 for non-splenectomy patients. However, these may not applicable to the Thai context because the values were higher than the utility from the Thai general population. Thus, we proportionally adjusted the utility of patients with and without splenectomy by benchmarking with the Thai general population utility (0.76). We divided the utility for splenectomized patients [48] by the utility of the general US population (0.86) [49] and converted it to the Thai context by multiplying with the utility of the Thai general population (0.766) [47] . The new utilities for splenectomized ITP patients and for non-splenectomy patients were 0.69 and 0.68, respectively. 
Cost-Effectiveness Analysis
Base-Case Analysis
Primary outcomes of interest were lifetime costs, QALYs gained, and the incremental cost-effectiveness ratio (ICER)/ QALY gained. For base-case analysis, we calculated the expected lifetime costs and outcomes for each treatment. All future costs and outcomes were discounted at a rate of 3 % per annum as recommended by the Thai HTA method guideline [50] . The results are presented as the ICER of IVIG ? standard treatment vs. standard treatment.
The interpretation of cost effectiveness of the findings was based on an official willingness-to-pay (WTP) of the Thai Health Economic Working Group threshold for drug listing in the NLEM 2012. They recommended a ceiling threshold of cost-effective intervention at $3,861 (120,000 THB) per QALY gained in 2012 [51, 52] .
Sensitivity Analysis
One-way sensitivity analyses were performed to investigate the effects of altering parameters within plausible ranges of 95 % CI, including all clinical effects, costs, utilities, and the discounting rate. The results of the one-way sensitivity analysis are presented using a tornado diagram (Fig. 3) . In addition, a probabilistic sensitivity analysis (PSA) was conducted to simultaneously examine the effects of all parameters of uncertainty using a Monte Carlo simulation performed by Microsoft Excel 2003 (Microsoft Corp., Redmond, WA, USA) [53] . The distributions of each probability were assigned as follows [54] : (a.) probability and utility parameters, in which their values were between zero and one, were specified to beta-distributions, (b.) costs, their characters were positively skewed and values were above zero, were assigned to gamma-distributions, and (c.) survival parameters were given to a log-normal distribution. A Monte Carlo simulation was run for 1,000 sets of the simulation to give a range of values for total costs, outcomes, and ICERs. Results of the PSA were presented as a cost-effectiveness acceptability curve (Fig. 4) . The expected net monetary benefit was calculated for the WTP of the NLEM 2012 threshold in Thailand to show the probability that IVIG is cost effective for monetary values that a decision maker might be willing to pay.
Results
Base-Case Analysis
Our base-case analysis demonstrated the estimated lifetime costs for IVIG plus standard treatment versus standard treatment as $8,199 and $6,868, respectively, while the estimated QALYs were 15.81, and 15.39 QALYs, respectively. Compared with the standard treatment of corticosteroids and platelet infusion, an incremental cost per QALY gained for adding IVIG was $3,172 per QALY gained (Table 2) . 0 500 1,000 1,500 2,000 2,500 3,000 3,500 4,000 4,500 5,000 5,500 6,000 6,500
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Cost per QALY (US $) Fig. 3 A series of one-way sensitivity analyses comparing the addition of IVIG to standard treatment and standard treatment alone. ITP idiopathic thrombocytopenic purpura
Sensitivity Analyses
A series of one-way sensitivity analyses (see Fig. 3 ) showed the most influential parameter was the probability of response to corticosteroids in patients who did not receive IVIG and did not undergo a splenectomy. When varying this probability from 0.60 to 0.48 and 0.72, the ICER was $2,308 and $5,915, respectively. The mortality rate among response patients was the second influential parameter. When varying this rate from 0.25 to 0.2 and 0.30, the cost-effectiveness value was $2,278 and $5,683, respectively. When varying direct medical costs of patients' responses to IVIG in short-term bleeding management during hospitalization to $774 and $1,963, the ICER was changed to $1,755 and $4,589. The result of 1,000 simulations of PSA showed IVIG plus standard treatment was estimated to have higher costs and was likely effective compared with standard treatment (Fig. 4a) . The cost-effectiveness acceptability curve showed that at a threshold value of $3,861, IVIG plus standard treatment have a 32.6 % likelihood of being cost effective when compared with the standard threshold (Fig. 4b) .
Discussion
Our findings demonstrated that the use of IVIG as an addition to standard treatment is cost effective for childhood ITP patients with life-threatening bleeding compared with standard treatment alone, given the consideration of the local context on the WTP value. However, our findings were highly sensitive. The findings can be used as supportive evidence for decision makers for the drug selection process of Thailand NLEM regarding resource allocation.
To our knowledge, our study is the first study that determined the cost effectiveness of IVIG used in childhood ITP patients with life-threatening bleeding. Two cost-effectiveness studies of IVIG in acute childhood ITP patients [55, 56] were previously published but none of them considered the life-threatening bleeding condition. In addition, our study estimated the cost effectiveness of adding IVIG to platelet transfusion and corticosteroids, which is standard treatment in Thailand, while both cost-effectiveness studies compared IVIG with other treatments including anti-D, prednisolone, intravenous methylprednisolone, and no treatment. ITP patients with life-threatening bleeding faced severe thrombocytopenia, thus they required a rapid rise in their platelet count to achieve adequate hemostasis. The international guidelines recommend a combination of treatments such as platelet transfusion combined with IVIG or IVIG with prednisolone, because a single therapy may take many hours or days to have an effect [10, 13] . Thus, our results may not be comparable to the previously published studies [55, 56] owing to the different context and indication.
We believe that our findings are highly valid and contextually relevant because of two main reasons. First, stakeholders were involved throughout the process of conducting our cost-effectiveness analysis. We invited different types of stakeholders and encouraged them to share their thoughts to make valid input parameters within a relevant context and increase the transparency of our work. Second, we used local data as much as possible in our analysis. We directly collected the mortality data from childhood ITP patients with life-threatening bleeding hospitalized in academic hospitals in Thailand. These make our results more reliable for the Thai context. Even though there is a lack of survival data for splenectomized patients in Thailand, we adjusted the mortality rates of these patients by incorporating the Thai age-specific mortality rate to reflect the Thai population [36] . Along with the lack of a utility value of ITP patients in Thailand, we also adjusted the utility of US-based patients to Thai patients by benchmarking with the Thai general population utility. All cost data were acquired from reliable local sources i.e., local hospital databases, national data from the Ministry of Public Health (MOPH) and Drugs and Medical Supplies MOPH.
A number of limitations in our study should be discussed. First, among 593 childhood ITP patients, we found only 24 childhood ITP patients with life-threatening bleeding from our hospital database. Even though a small number of patients were identified, it confirmed the previous findings that \1 % of childhood ITP patients may experience a life-threatening condition [3, 57, 58] . This may explain the cause of the limited number of patients in our cohort. Second, the probability of response to corticosteroids in patients who did not receive IVIG and no splenectomy and the mortality rate among response patients were the most influence parameters on the ICER. Further epidemiology studies are needed to control for other confounders that may affect these parameters such as co-morbidities and medication used. In addition, because of the limited number of patients identified from hospital databases, an increased number of hospital databases will increase the robustness of these two parameters. However, we derived these two parameters from hospital databases to reflect real effectiveness. Third, the final outcome such as bleeding control could not be extracted from the hospital database. Thus, we used the platelet level as a proxy of outcome evaluation. We assumed that all patients were hospitalized upon presentation, received treatments, and were not considered to respond until the platelet count had reached C20,000/lL. This criterion was set based on a literature review and discussion with clinical experts who were experienced in managing ITP patients with lifethreatening bleeding. The number of 20,000/lL is set to avoid ICH, which is the most serious and life-threatening complication likely to occur when the platelet count is \20,000/lL [59] . Fourth, our analysis assumed that all children responded to the initial treatment. Actually, a significant subpopulation of children may require additional treatments and resource uses. Thus, our treatment costs were likely to be underestimated. However, a previous large randomized trial showed that the rates of retreatment after failure from initial therapy were not different between patients receiving IVIG (26 %) and corticosteroids (15 %) [60] . Therefore, the incremental cost of our study may not be affected by this assumption. Last, the direct medical costs of the interventions were obtained from two hospital databases. They may not reflect actual clinical practice for all institutions in Thailand. However, two hospitals represented different hospital types from different regions; one tertiary-care regional hospital from the northern part of Thailand and one university hospital from the capital city of Thailand. These should illustrate to a certain extent the treatment pattern from different clinical practices. Last, the utility data were obtained from US data. This is identified as an area where further studies using local data are needed. However, the sensitivity analyses indicated that the ICER/QALY gained was not sensitive to changes in the utility data in our model.
Our findings showed cost-effectiveness results in a basecase analysis, but a sensitivity analysis was highly sensitive. Policy makers should interpret and use these findings as supportive evidence for their decisions; however, most of the decision making cannot be made solely on a costeffectiveness analysis. A budget impact analysis should be conducted to estimate the total budget needed for a government to implement this program. In addition, regular outcome monitoring such as the volume of medication used, mortality, and re-hospitalization should be performed along with the implementation suggested. This information can be used for further decision making related to ITP and other hematologic diseases.
Conclusion
The use of IVIG in addition to standard treatment is considered an appropriate option for childhood ITP patients with life-threatening bleeding, as it is effective and possibly cost effective throughout the patient's lifetime. However, our results were highly sensitive. Policy makers may consider our findings as part of the information for their decision making. Budget impact, public health impact, and ethical issues should be considered in the final decision making process.
